AI vendor review in healthcare is no longer just a security check. It is now tied to patient care, privacy, cyber risk, and legal exposure.

If I had to sum up the article in plain English, it’s this: hospitals can’t treat AI vendors like standard software vendors anymore. In 2025, healthcare saw 2x more breaches than in 2024, and one AI vendor breach exposed 1.4 million patient records. At the same time, ECRI named AI-enabled health tech the #1 healthcare technology hazard for 2025 because of bias, misleading outputs, and performance decline.

Here’s what matters most:

  • Security reviews alone are not enough
  • Model drift, bad outputs, and weak oversight can affect patient care
  • Hospitals now check training data, validation, bias testing, and rollback plans
  • PHI use, data ownership, retention, and model-training rights must be clear in the contract
  • Higher-risk tools need deeper review before and after go-live
  • Vendors need proof, not broad claims like “HIPAA-compliant”

If I were reviewing this topic for a hospital team, I’d focus on three questions first:

  1. What can this AI tool affect?
  2. What patient data does it touch?
  3. What happens if it gives the wrong answer or changes over time?

That shift is the whole point of this article. It shows that AI due diligence now covers the full life cycle of a tool: from intake and contracting to monitoring, incident response, and shutdown if needed.

The bottom line: AI vendor scrutiny is getting tougher because the risk is no longer limited to IT systems. It can reach patients, clinicians, and the health system itself.

Why healthcare AI vendors face deeper scrutiny now

Hospitals now lean on AI vendors for both clinical and day-to-day operating decisions. That changes the stakes. Vendor risk can turn into patient risk. As more AI-enabled tools enter care delivery, hospitals are taking a much harder look at third parties because model risk, hidden dependencies, and security gaps can ripple into patient care.

Old-school vendor reviews often miss the parts that matter most with AI. A standard software checklist may cover uptime, access controls, and contract terms, but it often skips things like model updates, training data sources, and the fact that outputs can shift over time. AI systems can also rely on behind-the-scenes third parties that standard risk tools don’t catch. So the review process has moved from a static checklist to lifecycle oversight.

AI contracts now need to spell out BAA coverage, data ownership, training restrictions, and rollback rights. Those terms matter because a model may behave one way at launch and another way later.

Guidance across the industry now treats AI risk as something that has to be managed across the full lifecycle, from use-case justification all the way through decommissioning.

AI creates security and privacy risks hospitals cannot overlook

AI brings its own set of cybersecurity and privacy concerns. That includes synthetic data misuse, training data leakage, and model manipulation attacks [1]. Because of that, AI due diligence is no longer just a procurement step. It’s also a security and privacy review.

A recent breach tied to a healthcare AI vendor exposed the records of 1.4 million patients [1]. That kind of event shows why hospitals can’t treat AI incidents like ordinary software problems. In many cases, the damage unfolds over time and calls for specialized forensics.

Clinical safety, bias, and trust are now part of the risk picture

Hospitals are also looking at whether AI systems stay safe and reliable after go-live. Model drift, bias, weaker performance, and security integrity issues, especially after vendor updates, can all affect clinical safety [1]. That’s why safety checks, bias monitoring, and model transparency now sit alongside security and privacy controls in vendor risk review.

In practice, hospitals want clear answers to a few hard questions:

  • How does the vendor validate models before deployment?
  • How is performance monitored after updates?
  • What happens when outputs shift or get worse?

That’s why hospitals now examine model transparency, PHI handling, bias controls, cybersecurity posture, and incident readiness.

What hospitals examine when reviewing AI vendors

Hospital teams now zero in on three things when they review an AI vendor: how the model works, how PHI is handled, and what happens when safety or security breaks down. The first area is model transparency and lifecycle control.

Model transparency, data provenance, and lifecycle controls

Hospitals ask vendors to spell out the intended use case, where the training data came from, how validation was done, and how the model performs across patient subgroups by race, sex, and age.[3][5][7]

They also want to see how often the model is revalidated, what triggers a rollback after clinical harm, performance drift, or a security incident, and what the shutdown process looks like if the tool needs to come offline.[3][5][7]

Many guidance frameworks now call for an AI Bill of Materials (AI BOM) that lists the models, datasets, APIs, cloud services, and key fourth parties involved.[2] In practice, a full AI BOM usually covers:

  • Core models and version numbers
  • Training and fine-tuning datasets
  • External APIs and microservices
  • Cloud providers and hosting regions
  • Open-source components
  • Fourth-party services, such as annotation vendors or MLOps platforms

PHI handling, privacy controls, and data rights

If a vendor touches PHI, hospitals check for the basics first: encryption in transit and at rest, role-based access controls, multi-factor authentication, logical segregation of customer data, and audit logs that show who accessed what and when.[4][6][8][11]

Then the contract gets a hard look. Hospitals often push back when vendors claim broad rights to reuse PHI to train other models, or when aggregation language is so broad that reidentification still feels possible. In plain terms, the hospital wants to know: Who owns the data, who owns the output, and where does all of it go?

That’s why hospitals should require ownership of inputs and outputs, limit training reuse, set data-retention and deletion terms, and verify where PHI is stored and processed.[3][4][5][9][10]

Hospitals then check whether those data practices match the vendor’s safety and security controls.

Bias testing, safety controls, cybersecurity posture, and incident readiness

Hospitals now review bias testing, safety controls, cybersecurity posture, and incident response as one connected set of issues. That makes sense. A gap in one area can spill into another and affect patient care.

On bias, vendors are expected to show testing across demographic groups, a mitigation plan when disparities appear, and a process for monitoring after deployment.[7][13] On safety, hospitals expect mandatory human review before AI output affects care, clear override thresholds, and fallback procedures in case the AI is turned off.[3][5][7]

Cybersecurity reviews look for hardened infrastructure, network segmentation, intrusion detection, centralized audit logging, and monitoring that can catch model abuse or data poisoning attempts.[5][8][11] Hospitals are also asking how vendors handle AI-related adverse events, including whether those events are tracked separately in vendor risk logs.[12][14]

These topics shape the due diligence questions, red flags, and contract terms.

How healthcare organizations can evaluate AI vendors more rigorously

Healthcare AI Vendor Risk Tiers: A 4-Level Framework for 2025

Healthcare AI Vendor Risk Tiers: A 4-Level Framework for 2025

Knowing what to check is only half the work. The other half is building a process teams can use again and again, so every AI vendor gets the right level of review - not so light that risk slips through, and not so heavy that the whole thing grinds to a halt. The aim is simple: match the depth of review to patient safety, privacy, and cyber risk.

Start with inherent risk: define the use case, data exposure, and clinical impact

Before sending even one questionnaire, intake teams need to answer a basic question: how much harm could this tool cause if it fails? That comes down to three things: what data it touches, what decisions it affects, and how much autonomy it has.

A simple place to start is a four-tier model:

  • Tier 1: Non-clinical tools with no PHI - such as a public website chatbot
  • Tier 2: Operational tools with limited PHI exposure - such as staffing optimization or billing help
  • Tier 3: Clinical decision support that reads imaging, labs, or notes to suggest diagnoses or treatment
  • Tier 4: Autonomous or semi-autonomous tools involved in dose calculation, ICU monitoring, or surgical assistance, where failure can affect patient safety

That tier should drive the review path. Some tools may stay within procurement. Others may need clinical validation or executive sign-off. A 1–5 scoring matrix for data sensitivity, clinical impact, and operational criticality gives procurement a steady way to assign tiers.

Use focused due diligence questions and watch for red flags

Once the tier is set, use the same question set across vendors. That keeps reviews consistent and makes it easier to spot weak answers. The table below breaks out the main risk areas, what solid answers look like, and what should make teams pause.

Risk Domain Key Due Diligence Questions Positive Indicators Red Flags
Training data & representativeness What datasets were used to train and fine-tune the model? What is the demographic and clinical composition of the training data? Has the model been externally validated, and can we validate it locally? Multi-site validation, published peer-reviewed results, subgroup metrics, local validation support No training data description, no demographic breakdown, no external validation
Model documentation & lifecycle What documentation is available on model design, intended use, and limitations? How often is the model revalidated or monitored for drift? How are material model changes handled? Detailed model docs, documented revalidation, continuous monitoring, recalibration support No model documentation, vague update process, no drift monitoring
PHI reuse & data rights Is PHI used only to provide the contracted service, or is it reused for model training, product improvement, or analytics? Are de-identified datasets derived from PHI governed clearly? What are the retention and deletion terms? Explicit PHI reuse restrictions, governed de-identified analytics, documented deletion with attestation Vague "improve our services" language, refusal to limit PHI reuse, no deletion evidence
BAA & regulatory alignment Does the vendor sign a HIPAA BAA? Are subcontractors and cloud providers covered? What breach notification timeframes, indemnification terms, and audit rights are included? BAA with subprocessor coverage, 48–72 hour breach notification, indemnification for vendor negligence, audit rights Unwilling to sign a BAA, generic breach terms, no subprocessor disclosure
Cybersecurity posture Do you maintain a formal security program? Do you hold SOC 2 Type II or HITRUST? When was your last third-party penetration test? How is your SDLC secured? Current SOC 2 Type II or HITRUST, recent third-party pen test, documented secure SDLC No independent assessments, outdated certifications, no vulnerability management
AI-specific controls What protections exist against prompt injection? How do you detect and prevent data poisoning during training or fine-tuning? Are model outputs monitored and escalated when needed? Input validation, context isolation, dataset integrity checks, anomaly detection, output monitoring with escalation No AI-specific threat coverage, no output monitoring, no escalation process
Bias & safety controls How is bias tested across subgroups? What are the override, escalation, and fallback procedures? Subgroup fairness metrics with defined thresholds, clinician oversight, documented fallback No bias testing, no override mechanism, no fallback if AI goes offline

Ask for evidence, not slogans. A vendor saying it is "HIPAA-compliant" does not prove much on its own. Teams should ask for a signed BAA, written controls, and test results.

Connect findings to governance decisions, contracts, and ongoing monitoring

Due diligence should shape what happens next. It should not just end up as a finished questionnaire in a folder. For Tier 3–4 tools, findings should feed a formal risk-benefit review by the CISO, compliance leader, and clinical governance committee before any approval is given for security, compliance, and clinical governance. For every tier, gaps found during review should turn into contract terms, not casual promises made on calls.

Contracts with AI vendors should go past standard BAA language. They should spell out PHI reuse limits, data retention and deletion timelines with attestation rights, breach notification windows, and the vendor’s duty to notify the health system of significant model changes. The ONC HTI-1 rule reinforces federal transparency and risk-management expectations for AI/ML tools used in healthcare decision-making.[15][16]

After deployment, the work is not over. Health systems should define key risk indicators (KRIs) and key performance indicators (KPIs) tied to model performance, safety events, privacy exceptions, and security incidents. Reassessment triggers should also be written into the contract - especially for significant model changes and security incidents - so monitoring becomes part of day-to-day operations, not something teams remember only after a problem shows up. Those same requirements should then carry into ongoing monitoring and reassessment.

How to build AI vendor governance with Censinet - and how vendors can prepare

Embed AI checkpoints into third-party risk and oversight workflows

Once risk tiers and contract terms are in place, hospitals need a workflow they can use again and again. The goal is simple: make AI review part of the normal path from planning to long-term oversight.

That means adding AI checkpoints at each stage: planning, onboarding, contracting, implementation, and ongoing monitoring. Higher-risk AI tools should go through review by security, clinical, legal, privacy, compliance, and IT teams before approval. No shortcuts.

Each step should tie back to the core risk areas that matter most: model transparency, PHI handling, bias, safety, and incident response.

Use Censinet RiskOps™ and Censinet AI to scale deeper reviews

Censinet RiskOps

Censinet RiskOps™ acts as the central hub for third-party and AI risk work. Teams can use it to manage assessments, collect evidence, and maintain continuous oversight for clinical applications and medical devices.

Censinet AI™ handles the time-heavy parts of due diligence. That includes questionnaire completion, evidence summarization, and mapping fourth-party dependencies. It also routes findings and tasks to the right owners and summarizes risk in real time.

Vendors should come to procurement with evidence ready across those same risk areas. If they wait until review starts, things can bog down fast.

Vendor Preparation Area Required Artifacts/Controls
Data Privacy and Retention Controls Memory management settings; user-accessible controls to enable or disable memory; data deletion and retention policies [17]
Model Training Transparency Documentation of training data sources and opt-out mechanisms [17]
Cybersecurity Posture Vulnerability disclosure history; evidence of patching to address server compromise [18]
Traceability and Explainability Prompt, output, and memory logs; architecture diagrams showing data boundaries [17][19]
Compliance Readiness Security policy, incident response plan, model documentation, and data-processing terms [19]

If a vendor can't answer basic questions about memory, training data, or PHI handling, hospitals should expect a deeper review.

FAQs

How should hospitals tier AI vendor risk?

Hospitals should sort AI vendors by risk based on three things: possible patient harm, data sensitivity, and clinical impact.

That matters because not every AI tool deserves the same level of scrutiny. A system that handles PHI or shapes clinical decisions carries much more at stake than a low-impact admin tool.

High-risk tools need deeper checks. That includes quarterly risk assessments, bias audits, and thorough security reviews.

Lower-risk tools can often be reviewed once a year.

A centralized inventory of AI systems makes this much easier. It gives teams one place to see what’s in use, apply a risk-tiering framework, and put the most oversight on the tools with the biggest safety impact.

What contract terms matter most for AI vendors?

Healthcare AI contracts need more than basic software terms. In a clinical setting, the stakes are higher. A weak clause doesn’t just create IT trouble. It can put patient data, care quality, and legal exposure on the line.

They should include a HIPAA-compliant Business Associate Agreement. They should also block any use of patient data for model training unless the provider has explicit consent to do so. That point matters. A vendor may treat training use as routine, but for a healthcare company, it can be a major risk.

The contract should also require model transparency and advance notice before any material changes. If the vendor updates the model, changes how outputs are generated, or shifts core features, the customer shouldn’t find out after the fact. In healthcare, that kind of surprise can cause serious problems.

It also makes sense to spell out audit rights, liability, and indemnification for inaccurate outputs or hallucinations. If the system produces bad information and that leads to harm, the contract should say who is on the hook. The same goes for performance SLAs with remedies, along with clear terms for data ownership, rollback, and suspension.

What proof should AI vendors provide during review?

Go beyond generic security attestations and ask for proof across the full model lifecycle.

Vendors should share Model Cards or Fact Sheets that spell out intended use, training data demographics, known limits, and update frequency. They should also provide a verified AI Bill of Materials that lists model dependencies, subcontractors, and open-source assets.

That’s the baseline. You should also ask for documented testing that covers:

  • bias mitigation
  • data poisoning
  • model evasion
  • adversarial attacks

On top of that, require model-specific incident response playbooks and contract terms that protect audit rights and require notice of material updates.

Related Blog Posts